The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib

Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis

(2017) Juan-Carlos Hernández-Boluda et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

(2017) Srdan Verstovsek et al.   Journal of Hematology & Oncology

Does ruxolitinib prolong the survival of patients with myelofibrosis?

(2016) Francisco Cervantes et al.   BLOOD

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

(2016) C N Harrison et al.   LEUKEMIA

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

(2013) A. Tefferi et al.   BLOOD

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level

(2009) Jocelin Huang et al.   EUROPEAN JOURNAL OF HAEMATOLOGY